Myeloid Diseases News from Poster Sessions

Mutant IDH (mIDH) inhibitors, ivosidenib or enasidenib, with azacitidine (AZA) in patients with acute myeloid leukemia (AML). First Author: Courtney Denton Dinardo, The University of Texas MD Anderson Cancer Center, Houston, TX

Abstract 7042